Selexipag for the Treatment of Pulmonary Arterial Hypertension

20151,028 citationsJournal Articlebronze Open Access

Authors

Olivier Sitbon · Inserm

Richard N. Channick · Massachusetts General Hospital

Kelly Chin · The University of Texas Southwestern Medical Center

Aline Frey · Actelion (Switzerland)

Seán Gaine · Mater Misericordiae University Hospital

Nazzareno Galiè · University of Bologna

Hossein Ardeschir Ghofrani

Abstract

Among patients with pulmonary arterial hypertension, the risk of the primary composite end point of death or a complication related to pulmonary arterial hypertension was significantly lower with selexipag than with placebo. There was no significant difference in mortality between the two study groups. (Funded by Actelion Pharmaceuticals; GRIPHON ClinicalTrials.gov number, NCT01106014.).

Topics & Keywords

Pulmonary Hypertension Research and Treatments Cardiovascular Issues in Pregnancy Heart Failure Treatment and Management

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 373, Issue 26, pp. 2522-2533

DOI: 10.1056/nejmoa1503184

Field-Weighted Citation Impact: 69.72